title: A double blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis.
abstract: The treatment of digital ischemia in systemic sclerosis remains inadequate. We report a double blind, placebo controlled trial of recombinant tissue plasminogen activator (rtPA), a potent thrombolytic agent. Ten patients received rtPA. A potent, acute fibrinolytic effect was observed. During the infusion of rtPA, improvements in skin blood flow were seen. These improvements were shortlived.
authors.affiliation: Rheumatic Diseases Centre, University of Manchester, Salford, U.K.
authors.forename: P S
authors.initials: PS
authors.lastname: Klimiuk
authors.forename: E A
authors.initials: EA
authors.lastname: Kay
authors.forename: K J
authors.initials: KJ
authors.lastname: Illingworth
authors.forename: R J
authors.initials: RJ
authors.lastname: Gush
authors.forename: L J
authors.initials: LJ
authors.lastname: Taylor
authors.forename: R D
authors.initials: RD
authors.lastname: Baker
authors.forename: C
authors.initials: C
authors.lastname: Perkins
authors.forename: M I
authors.initials: MI
authors.lastname: Jayson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005385:Fingers / Q000098:blood supply*; D006801:Humans; D007511:Ischemia / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy*; D012867:Skin / Q000098:blood supply; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D010959:Tissue Plasminogen Activator